AxoGen (NASDAQ:AXGN) executives outlined a year of accelerating commercial momentum, recent balance sheet improvements, and the operational implications of its December Biologics License Application ...
CEO Jim Clemmer said the company has spent the last several years reshaping its portfolio and operating model, moving away ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果